| Identification | Back Directory | [Name]
6,12,15,18,21,24,27,30,33-Nonaoxa-3,9-diazapentatriacontanamide, 2-(4-aminobutyl)-35-[4-[[[[4-[(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)methyl]cyclohexyl]carbonyl]amino]methyl]-1H-1,2,3-triazol-1-yl]-N-[4-(hydroxymethyl)phenyl]-4,8-dioxo-, (2S)- | [CAS]
2616704-22-2 | [Synonyms]
6,12,15,18,21,24,27,30,33-Nonaoxa-3,9-diazapentatriacontanamide, 2-(4-aminobutyl)-35-[4-[[[[4-[(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)methyl]cyclohexyl]carbonyl]amino]methyl]-1H-1,2,3-triazol-1-yl]-N-[4-(hydroxymethyl)phenyl]-4,8-dioxo-, (2S)- | [Molecular Formula]
C50H79N9O16 | [MDL Number]
MFCD32201140 | [MOL File]
2616704-22-2.mol | [Molecular Weight]
1062.21 |
| Chemical Properties | Back Directory | [density ]
1.31±0.1 g/cm3(Predicted) | [solubility ]
DMSO : 200 mg/mL (188.29 mM; Need ultrasonic) | [form ]
Viscous Liquid | [pka]
13.10±0.46(Predicted) | [color ]
Colorless to light yellow |
| Hazard Information | Back Directory | [Biological Activity]
CL2A is a claevable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond. Labetuzumab govitecan used this linker[1]. | [References]
[1]. Samantha Congreve, et al. Antibody drug conjugates (ADC). Teknisk- naturvetenskaplig fakultet |
|
|